114138-49-7Relevant academic research and scientific papers
Hydrazones, ArNHN=CRCH2COX, from reactions of arylhydrazines, ArNHNH2, with 1,3-dicarbonyl compounds, RCOCH2COX(X = OR1 or NHPh): Crystal structures of (E)-4-O2NC 6H4NHN=CMeCH2CO2R1 (R1 = Me or Et) and (E)-PhNHN=CPhCH2CONHPh
De Lima, Geraldo M.,Wardell, James L.,Wardell, Solange M. S. V.
, p. 213 - 221 (2010)
The molecular and crystal structures of (E)-4-O2NC 6H4NHN=CMeCH2CO2R1 (4: R1 = Me; 5: R1 = Et) and (E)-PhNHN=CPhCH2CONHPh (6) are reported from data collected at 120(2) K. The major intermolecular interactions in both 4 and 5 involve the hydazonyl NH and the carbonyl oxygen, with formation of symmetric dimers. Due to 4 and 5 each having different sets of additional intermolecular interactions, different supramolecular arrays are produced: molecules of 4 are linked into a three-dimension structure, while zig-zag chains of molecules of 5 are obtained. Chains of molecules of 6, prepared from PhNHNH2 and PhCOCH2CONHPh, are obtained from intermolecular hydrogen bonds involving amido NH and carbonyl oxygen moieties. Further interactions, C-H-π(arene), C-H-O and π-π stacking interactions in 6 produces a three dimensional array. Compound 4 crystallizes in the triclinic space group P - 1 with a = 7.7027(2) A, b = 7.8103(2) A, c = 11.1761(3) A, α = 77.054(2)°, β = 79.425(2)°, γ = 81.097(2)°. Compound 5 crystallizes in the triclinic space group P - 1 with a = 5.6323(2)A, b = 9.9695(3)A, c = 11.0286(4)A, α = 91.859(2)°, β = 102.034(2)°, γ = 98.898(3)°. Compound 6 crystallizes in the monoclinic space group P21/c with a = 10.4255(8)A, b = 10.4255(8)A, c = 9.3368(5)A, β = 113.780(4) °.
Identification of small molecule inhibitors of human COQ7
Tsuganezawa, Keiko,Sekimata, Katsuhiko,Nakagawa, Yukari,Utata, Rei,Nakamura, Kana,Ogawa, Naoko,Koyama, Hiroo,Shirouzu, Mikako,Fukami, Takehiro,Kita, Kiyoshi,Tanaka, Akiko
, (2019/11/26)
Given that the associated clinical manifestations of ubiquinone (UQ, or coenzyme Q) deficiency diseases are highly heterogeneous and complicated, effective new research tools for UQ homeostasis studies are awaited. We set out to develop human COQ7 inhibit
New hydrazone derivatives of pyrazole-4-carboxaldehydes exhibited anti-inflammatory properties
Chen, Qiuyan,Deng, Xianqing,He, Shihui,Li, Sifan,Liang, Yuqiu,Liu, Bing,Song, Mingxia,Yu, Shengwang
, p. 501 - 510 (2020/04/17)
Background: Several series of hydrazone derivatives of pyrazole-4-carboxaldehydes (4-11) were designed and synthesized to screen their inflammatory activity. Methods: The products were characterized by1H NMR,13C NMR and HRMS. In vitro LPS-induced TNF-α model and in vivo xylene-induced ear-edema model were used to evaluate their anti-inflammatory activity. Results and Conclusion: Bioassays indicated that most of the compounds markedly inhibited the expression of TNF-α at the concentration of 10 μg/mL. Compounds 7b and 11c, two of the most potent compounds, exhibited TNF-α inhibitory ability in a dose-dependent manner with IC50 values of 5.56 and 3.69 μM, respectively. In vivo, intraperitoneal administration with 7b and 11c markedly inhibited the ear edema at the doses of 20 and 50 mg/kg. Compound 11c, inhibited edema by 49.59 % at the dose of 20 mg/kg, was comparable to the reference drug dexamethasone at the same dose (with an inhibition of 50.49 %). To understand the binding pattern, molecular docking of representa-tive 7b and 11c was performed, which demonstrated that both compounds have a forceful binding with the TNF-α, and that the phenyl and hydrazide moieties of them play a significant role in binding with the target site.
5-((1H-Pyrazol-4-yl)methylene)-2-thioxothiazolidin-4-one inhibitors of ADAMTS-5
Gilbert, Adam M.,Bursavich, Matthew G.,Lombardi, Sabrina,Georgiadis, Katy E.,Reifenberg, Erica,Flannery, Carl R.,Morris, Elisabeth A.
, p. 1189 - 1192 (2007/10/03)
A series of 5-((1H-pyrazol-4-yl)methylene)-2-thioxothiazolidin-4-one inhibitors of ADAMTS-5 (aggrecanase-2) is described. These compounds show μM functional inhibition of ADAMTS-5, and represent a new class of agents with the potential of inhibiting degradation of aggrecan, a major component of cartilage which is lost in osteoporosis. Compound 12 is noteworthy in that it has an ADAMTS-5 IC50: 1.1 μM and shows >40-fold functional selectivity over ADAMTS-4 (aggrecanase-1).
